Gastrointestinal stromal tumours: Consensus statement on diagnosis and treatment

Canadian Journal of Gastroenterology

Volumn 20, Issue 3, 2006, Pages 157-163

  Blackstein, Martin E ^a   Blay, Jean Yves ^b   Corless, Christopher ^c   Driman, David K ^d   Riddell, Robert ^a   Soulières, Denis ^e   Swallow, Carol J ^a   Verma, Shailendra ^f   Bégin, Louis R ^g   Dubé, Pierre ^e   Figueredo, Alvarado ^h   Haider, Massom ⁱ   Khalili, Korosh ⁱ   Knowling, Margaret ^j   Law, Calvin ^k   L'Espérance, Bernard ^g   Morris, Donald ^l   Mulder, Karen ^m   Owen, David ⁿ   Pollett, Aaron ^a   Rorke, Stewart ^o   Wong, Ralph ^p   Younus, Jawaid ^q   more..

^a MOUNT SINAI HOSPITAL   (Canada)

^b UNIVERSITÉ LYON 1   (France)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^d UNIVERSITY OF WESTERN ONTARIO   (Canada)

^e CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^f OTTAWA REGIONAL CANCER CENTRE   (Canada)

^g HÔPITAL DU SACRÉ COEUR DE MONTRÉAL   (Canada)

^h JURAVINSKI CANCER CENTRE   (Canada)

ⁱ PRINCESS MARGARET HOSPITAL   (Canada)

^j BRITISH COLUMBIA CANCER AGENCY   (Canada)

^k SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^l TOM BAKER CANCER CENTRE   (Canada)

^m CROSS CANCER INSTITUTE   (Canada)

ⁿ VANCOUVER GENERAL HOSPITAL   (Canada)

^o Dr H Bliss Murphy Cancer Centre   (Canada)

^p ST BONIFACE GENERAL HOSPITAL   (Canada)

^q LONDON REGIONAL CANCER PROGRAM   (Canada)

more..

Author keywords

Consensus; Gastrointestinal stromal tumour; Imatinib; Oncology; Treatment

Indexed keywords

IMATINIB; SUNITINIB;

ADJUVANT THERAPY; ADVISORY COMMITTEE; ARTICLE; CANADA; CHEMOTHERAPY; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONSENSUS; DIAGNOSTIC PROCEDURE; DRUG DOSE REGIMEN; DRUG INDUSTRY; FOLLOW UP; GASTROINTESTINAL RADIOGRAPHY; GASTROINTESTINAL STROMAL TUMOR; GASTROINTESTINAL SURGERY; GENOTYPE; HIGH RISK PATIENT; HUMAN; METASTASIS; MORBIDITY; PATHOLOGY; PATIENT CARE; PRIORITY JOURNAL; RECURRENCE RISK; TREATMENT FAILURE; TUMOR RECURRENCE;

EID: 33645926705     PISSN: 08357900     EISSN: None     Source Type: Journal    
DOI: 10.1155/2006/434761     Document Type: Article

References (49)

1. Miettinen M, Sarlomo-Rikala M, Lasota J. Gastrointestinal stromal tumours. Ann Chir Gynaecol 1998;87:278-81.
2. Hasegawa T, Matsuno Y, Shimoda T, Hirohashi S. Gastrointestinal stromal tumor: Consistent CD117 immunostaining for diagnosis, and prognostic classification based on tumor size and MIB-1 grade. Hum Pathol 2002;33:669-76.
3. Nilsson B, Bumming P, Meis-Kindblom JM, et al. Gastrointestinal stromal tumors: The incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era. Cancer 2005;103:821-9.
4. Di Matteo G, Pescarmona E, Peparini N, et al. Histopathological features and clinical course of the gastrointestinal stromal tumors. Hepatogastroenterology 2002;49:1013-6.
5. Tornoczky T, Kalman E, Hegedus G, et al. High mitotic index associated with poor prognosis in gastrointestinal autonomic nerve tumour. Histopathology 1999;35:121-8.
6. Fletcher CD, Berman JJ, Corless C, et al. Diagnosis of gastrointestinal stromal tumors: A consensus approach. Hum Pathol 2002;33:459-65.
7. Miettinen M, Sobin LH, Lasota J. Gastrointestinal stromal tumors of the stomach: A clinicopathologic, immunohistochemical, and molecular genetic study of 1765 cases with long-term follow-up. Am J Surg Pathol 2005;29:52-68.
8. Miettinen M, Kopczynski J, Makhlouf HR, et al. Gastrointestinal stromal tumors, intramural leiomyomas, and leiomyosarcomas in the duodenum: A clinicopathologic, immunohistochemical, and molecular genetic study of 167 cases. Am J Surg Pathol 2003;27:625-41.
9. Hirota S, Isozaki K, Moriyama Y, et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 1998;279:577-80.
10. Heinrich MC, Corless CL, Duensing A, et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science 2003;299:708-10.
11. Rubin BP, Singer S, Tsao C, et al. KIT activation is a ubiquitous feature of gastrointestinal stromal tumors. Cancer Res 2001;61:8118-21.
12. Demetri GD. Targeting c-kit mutations in solid tumors: Scientific rationale and novel therapeutic options. Semin Oncol 2001;28:19-26.
13. Kinoshita K, Isozaki K, Hirota S, et al. c-kit gene mutation at exon 17 or 13 is very rare in sporadic gastrointestinal stromal tumors. J Gastroenterol Hepatol 2003;18:147-51.
14. van Oosterom AT, Judson IR, Verweij J, et al. Update of phase I study of imatinib (STI571) in advanced soft tissue sarcomas and gastrointestinal stromal tumors: a report of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 2002;38(suppl 5):S83-7.
15. Benjamin RS, Rankin C, Fletcher J, et al. Phase III dose-randomized study of imatinib mesylate (STI 571) for GIST: Intergroup S0033 early results. Proc Am Soc Clin Oncol 2003;22:814. (Abst)
16. Dagher R, Cohen M, Williams G, et al. Approval summary: Imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors. Clin Cancer Res 2002;8:3034-8.
17. Blackstein ME, Rankin C, Fletcher CD, et al. Clinical benefit of imatinib (IM) in patients (pts) with metastatic gastrointestinal stromal tumors negative for expression of CD117 (KIT GIST) in the S0033 Phase III trial. Presented at the American Association of Clinical Oncology (ASCO) annual meeting, Orlando, Florida, May 13-17, 2005. (Abst)
18. Demetri GD, Benjamin R, Blanke CD, et al. NCCN Task Force Report: Optimal management of patients with gastrointestinal stromal tumor (GIST) - expansion and update of NCCN clinical practice guidelines. JNCCN 2004;2(Suppl 1):S1-S26.
19. Blay JY, Bonvalot S, Casali P, et al. Consensus meeting for the management of gastrointestinal stromal tumors. Report of the GIST Consensus Conference of 20-21 March 2004, under the auspices of ESMO. Ann Oncol 2005;16:566-78.
20. Blackstein ME, Dube P, Fletcher JA, et al. Gastrointestinal stromal tumours: Etiology, pathology and clinical management. Can J Gastroenterol 2004;18 Suppl B:3B-8B.
21. Plaat BE, Hollema H, Molenaar WM. Soft tissue leiomyosarcomas and malignant gastrointestinal tumors: Differences in clinical outcome and expression of multidrug resistance proteins. J Clin Oncol 2000;18:3211-20.
22. Blay P, Astudillo A, Buesa JM, et al. Protein kinase C theta is highly expressed in gastrointestinal stromal tumors but not in other mesenchymal neoplasias. Clin Cancer Res 2004;10):4089-95.
23. Debiec-Rychter M, Dumez H, Judson I, et al. Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 2004;40:689-95.
24. Bauer S, Corless CL, Heinrich MC, et al. Response to imatinib mesylate of a gastrointestinal stromal tumor with very low expression of KIT. Cancer Chemother Pharmacol 2003;51:261-5.
25. Corless CL, Schroeder A, Griffith D, et al. PDGFRA mutations in gastrointestinal stromal tumors: Frequency, spectrum and in vitro sensitivity to imatinib. J Clin Oncol 2005;23:5357-64.
26. Goerres GW, Stupp R, Barghouth G, et al. The value of PET, CT and in-line PET/CT in patients with gastrointestinal stromal tumours: long-term outcome of treatment with imatinib mesylate. Eur J Nucl Med Mol Imaging 2005;32:153-62.
27. Therasse P, Arbuck SG, Eisenhauer E, et al. New guidelines to evaluate the response to treatment in solid tumours. J Natl Cancer Inst 2000;92:205-16.
28. Choi H, Charnsangavej C, de Castro Faria S, et al. CT evaluation of the response of gastrointestinal stromal tumors after imatinib mesylate treatment: a quantitative analysis correlated with FDG PET findings. AJR Am J Roentgenol 2004;183:1619-28.
29. Linton KM, Taylor MB, Radford JA. Response evaluation in GIST treated with imatinib - misdiagnosis of disease progression on CT due to cystic change in liver metastases (abst 9047). Presented at the American Association of Clinical Oncology (ASCO) annual meeting, Orlando, Florida, May 13-17, 2005.
30. Shankar S, Vansonnenberg E, Desai J, Dipiro PJ, Van Den Abbeele A, Demetri GD. Gastrointestinal Stromal Tumor: New Nodule-within-a-Mass Pattern of Recurrence after Partial Response to Imatinib Mesylate. Radiology 2005;235:892-8.
31. Stroobants S, Goeminne J, Seegers M, et al. 18FDG-Positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec). Eur J Cancer 2003;39:2012-20.
32. Vanel D, Albiter M, Shapeero L, et al. Role of computed tomography in the follow-up of hepatic and peritoneal metastases of GIST under imatinib mesylate treatment: A prospective study of 54 patients. Eur J Radiol 2005;54:118-23.
33. Ng EH, Pollock RE, Munsell MF, Atkinson EN, Romsdahl MM. Prognostic factors influencing survival in gastrointestinal leiomyosarcomas. Implications for surgical management and staging. Ann Surg 1992;215:68-77.
34. Crosby JA, Catton CN, Davis A, et al. Malignant gastrointestinal stromal tumors of the small intestine: A review of 50 cases from a prospective database. Ann Surg Oncol 2001;8:50-9.
35. Chen TW, Liu HD, Shyu RY, et al. Giant malignant gastrointestinal stromal tumors: recurrence and effects of treatment with STI-571. World J Gastroenterol 2005;11:260-3.
36. DeMatteo RP, Lewis JJ, Leung D, Mudan SS, Woodruff JM, Brennan MF. Two hundred gastrointestinal stromal tumors: Recurrence patterns and prognostic factors for survival. Ann Surg 2000;231:51-8.
37. Bauer S, Hartmann JT, Lang H, et al. Imatinib may enable complete resection in previously unresectable or metastatic GIST. Proc Am Soc Clin Oncol 2004;23:819. (Abst)
38. Katz D, Segal A, Alberton Y, et al. Neoadjuvant imatinib for unresectable gastrointestinal stromal tumor. Anticancer Drugs 2004;15:599-602.
39. Hohenberger P, Bauer S, Schneider U, et al. Tumor resection following imatinib pretreatment in GI stomal tumors (abst 3288). Presented at the 39th annual meeting of the American Society of Clinical Oncology, Chicago IL, May 31-June 3, 2003.
40. Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002;347:472-80.
41. Bumming P, Andersson J, Meis-Kindblom JM, et al. Neoadjuvant, adjuvant and palliative treatment of gastrointestinal stromal tumours (GIST) with imatinib: A centre-based study of 17 patients. Br J Cancer 2003;89:460-4.
42. Okubo K, Yamao K, Nakamura T, et al. Endoscopic ultrasound-guided fine-needle aspiration biopsy for the diagnosis of gastrointestinal stromal tumors in the stomach. J Gastroenterol 2004;39:747-53.
43. Blay J-Y, Berthaud P, Perot D, et al. Continuous vs. intermittent imatinib treatment in advanced GIST after one year: A prospective randomized phase III trial of the French Sarcoma Group. Proc Am Soc Clin Oncol 2004;23:815. (Abst)
44. Zalcberg JR, Verweij J, Casali PG, et al. Outcome of patients with advanced gastro-intestinal stromal tumours (GIST) crossing over to a daily imatinib dose of 800 mg after progression on 400 mg. Eur J Cancer 2005;41:1751-7.
45. Verweij J, Casali PG, Zalcberg J, et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: Randomised trial. Lancet 2004;364:1127-34.
46. Heinrich MC, Shoemaker JS, Corless CL, et al. Correlation of target kinase genotype with clinical activity of imatinib mesylate (IM) in patients with metastatic GI stromal tumors (GISTs) expressing KIT (KIT+). Proc Am Soc Clin Oncol 2005;23:3S. (Abst)
47. Ray-Coquard I, Pérol D, Bui BN, et al. Prognostic factors for progression free and overall survival in advanced GIST: Results from the BFR14 phase III trial of the French Sarcoma Group. Presented at the American Association of Clinical Oncology (ASCO) annual meeting, Orlando, Florida, May 13-17, 2005. (Abst)
48. Demetri GD, van Oosterom AT, Blackstein M, et al. Phase 3, multicenter, randomized, double-blind, placebo-controlled trial of SU11248 in patients (pts) following failure of imatinib for metastatic GIST. Presented at the American Association of Clinical Oncology (ASCO) annual meeting, Orlando, Florida, May 13-17, 2005. (Abst)
49. Dileo P, Randhawa R, Vansonnenberg E, et al. Safety and efficacy of percutaneous radio-frequency ablation (RFA) in patients (pts) with metastatic gastrointestinal stromal tumor (GIST) with clonal evolution of lesions refractory to imatinib mesylate (IM). Proc Am Soc Clin Oncol 2004;23:818. (Abst)